Log in
NASDAQ:CABA

Cabaletta Bio Stock Forecast, Price & News

$12.06
+0.47 (+4.06 %)
(As of 10/23/2020 12:00 AM ET)
Add
Compare
Today's Range
$11.33
Now: $12.06
$12.21
50-Day Range
$9.71
MA: $10.89
$12.15
52-Week Range
$5.51
Now: $12.06
$19.63
Volume43,200 shs
Average Volume105,315 shs
Market Capitalization$289.92 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies. Its product candidate pipeline also include MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; FVIII-CAART, a discovery stage product to treat a subset of patients with Hemophilia A; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. Cabaletta Bio, Inc. has a collaboration with the University of Pennsylvania; and research agreement with The Regents of the University of California. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was founded in 2017 and is headquartered in Philadelphia, Pennsylvania.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.44 out of 5 stars

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CABA
CUSIPN/A
CIKN/A
Phone267-759-3100
Employees31

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$5.76 per share

Profitability

Net Income$-16,940,000.00

Miscellaneous

Market Cap$289.92 million
Next Earnings Date11/5/2020 (Estimated)
OptionableNot Optionable
$12.06
+0.47 (+4.06 %)
(As of 10/23/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CABA News and Ratings via Email

Sign-up to receive the latest news and ratings for CABA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Cabaletta Bio (NASDAQ:CABA) Frequently Asked Questions

How has Cabaletta Bio's stock been impacted by Coronavirus (COVID-19)?

Cabaletta Bio's stock was trading at $11.23 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CABA stock has increased by 7.4% and is now trading at $12.06.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Cabaletta Bio?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cabaletta Bio in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Cabaletta Bio
.

When is Cabaletta Bio's next earnings date?

Cabaletta Bio is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Cabaletta Bio
.

How were Cabaletta Bio's earnings last quarter?

Cabaletta Bio, Inc. (NASDAQ:CABA) issued its quarterly earnings results on Thursday, August, 6th. The company reported ($0.35) EPS for the quarter, topping the Zacks' consensus estimate of ($0.39) by $0.04.
View Cabaletta Bio's earnings history
.

What price target have analysts set for CABA?

4 equities research analysts have issued twelve-month price targets for Cabaletta Bio's shares. Their forecasts range from $20.00 to $25.00. On average, they expect Cabaletta Bio's stock price to reach $21.67 in the next twelve months. This suggests a possible upside of 79.7% from the stock's current price.
View analysts' price targets for Cabaletta Bio
.

Who are some of Cabaletta Bio's key competitors?

What other stocks do shareholders of Cabaletta Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cabaletta Bio investors own include Alector (ALEC), Editas Medicine (EDIT), Kaleido Biosciences (KLDO), Sorrento Therapeutics (SRNE), Homology Medicines (FIXX), Skyworks Solutions (SWKS), CrowdStrike (CRWD), Precision BioSciences (DTIL), InVitae (NVTA) and Pfizer (PFE).

Who are Cabaletta Bio's key executives?

Cabaletta Bio's management team includes the following people:
  • Dr. Steven A. Nichtberger, Co-Founder, Chairman, CEO & Pres (Age 59, Pay $782.16k)
  • Mr. Anup Marda M.B.A., Chief Financial Officer (Age 43, Pay $548.2k)
  • Dr. Gwendolyn K. Binder, Exec. VP of Science & Technology (Age 45, Pay $582.89k)
  • Dr. Michael C. Milone M.D., Ph.D., Co-Founder & Co-Chair of Scientific Advisory Board
  • Dr. Aimee Payne M.D., Ph.D., Co-Founder & Co-Chair of Scientific Advisory Board
  • Mr. J. Brian Stalter J.D., Gen. Counsel (Age 48)
  • Ms. Martha O'Connor, Chief HR Officer
  • Dr. David J. Chang M.D., M.P.H., Chief Medical Officer (Age 57)

When did Cabaletta Bio IPO?

(CABA) raised $87 million in an initial public offering (IPO) on Friday, October 25th 2019. The company issued 5,800,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, Cowen and Company and Evercore Group acted as the underwriters for the IPO.

What is Cabaletta Bio's stock symbol?

Cabaletta Bio trades on the NASDAQ under the ticker symbol "CABA."

How do I buy shares of Cabaletta Bio?

Shares of CABA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Cabaletta Bio's stock price today?

One share of CABA stock can currently be purchased for approximately $12.06.

How big of a company is Cabaletta Bio?

Cabaletta Bio has a market capitalization of $289.92 million. The company earns $-16,940,000.00 in net income (profit) each year or ($4.07) on an earnings per share basis. Cabaletta Bio employs 31 workers across the globe.

What is Cabaletta Bio's official website?

The official website for Cabaletta Bio is www.cabalettabio.com.

How can I contact Cabaletta Bio?

Cabaletta Bio's mailing address is 2929 ARCH STREET SUITE 600, PHILADELPHIA PA, 19104. The company can be reached via phone at 267-759-3100 or via email at [email protected]

This page was last updated on 10/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.